Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study

Table 2 Dosing of anti-TNFs as first or subsequent line biologic therapy and abatacept

^aPatient weight.
^bRecommended doses are 500 mg for patients < 60 kg, 750 mg for patients 60 to 100 kg, 1000 mg for patients > 100 kg.
^cStarting doses for etanercept and adalimumab defined as the average daily dose of the first fill, which was converted to milligrams per the label treatment interval by multiplying by the appropriate number of days. The starting infliximab and abatacept infusion doses are reported as milligrams administered.
^dMaintenance dose defined as the recorded dose of the third administration (infliximab and abatacept) or average daily dose (converted to milligrams per the recommended treatment interval) for the third prescription fill (etanercept and adalimumab) among patients who had at least 3 infusions/fills before discontinuation (> 90 day gap).
^eAverage daily dose calculated over the 1-year follow-up period (etanercept, adalimumab) or for the post-loading period (infliximab, abatacept) and converted to the label treatment interval by multiplying by the appropriate number of days.
^fRequires at least 3 infusions.
^gRequires at least 5 prescriptions fills or infusions.
^hLast dose defined as the recorded dose of the last administration (infliximab and abatacept) or average daily dose (converted to milligrams per the recommended treatment interval) for the last prescription fill (etanercept and adalimumab).

ISSN: 1471-2474